New insights into pancreatic cancer-induced paraneoplastic diabetes

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 7, 2013, Pages 423-433

  Sah, Raghuwansh P ^a   Nagpal, Sajan Jiv Singh ^a   Mukhopadhyay, Debabrata ^b   Chari, Suresh T ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; FATTY ACID; GLUCOSE; INSULIN;

ADIPOSE TISSUE; ADIPOSE TISSUE INFLAMMATION; ANATOMICAL VARIATION; CACHEXIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE DURATION; EARLY DIAGNOSIS; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOXEMIA; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPOLYSIS; NEW ONSET DIABETES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONSET AGE; PANCREAS CANCER; PANCREAS INSUFFICIENCY; PANCREAS ISLET DISEASE; PARANEOPLASTIC DIABETES; PARANEOPLASTIC SYNDROME; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PANCREATIC NEOPLASMS; PREVALENCE; TIME FACTORS; WEIGHT LOSS;

EID: 84879974685     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.49     Document Type: Review

References (150)

1. Jemal, A. et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Conlon, K. C., Klimstra, D. S. & Brennan, M. F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg. 223, 273-279 (1996).
3. Chari, S. T. Detecting early pancreatic cancer: problems and prospects. Semin. Oncol. 34, 284-294 (2007).
4. Magruder, J. T., Elahi, D. & Andersen, D. K. Diabetes and pancreatic cancer: chicken or egg? Pancreas 40, 339-351 (2011).
5. Li, D. Diabetes and pancreatic cancer. Mol. Carcinog. 51, 64-74 (2012).
6. Cui, Y. & Andersen, D. K. Diabetes and pancreatic cancer. Endocr. Relat. Cancer 19, F9-F26 (2012).
7. Bright, R. Cases and observations connected with disease of the pancreas and duodenum. Med. Chir. Trans. 18, 1-56 (1833).
8. Marble, A. Diabetes and pancreatic cancer. N. Engl. J. Med. 211, 339-349 (1934).
9. Grauer, F. W. Pancreatic carcinoma: a review of thirty-four autopsies. Arch. Intern. Med. 63, 884-889 (1939).
10. Green, R. C. Jr, Baggenstoss, A. H. & Sprague, R. G. Diabetes mellitus in association with primary carcinoma of the pancreas. Diabetes 7, 308-311 (1958).
11. Everhart, J. & Wright, D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273, 1605-1609 (1995).
12. Huxley, R., Ansary-Moghaddam, A., Berrington de Gonzalez, A., Barzi, F. & Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92, 2076-2083 (2005).
13. Ben, Q. et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur. J. Cancer 47, 1928-1937 (2011).
14. Grote, V. A. et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 54, 3037-3046 (2011).
15. Ogawa, Y. et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 94, 2344-2349 (2002).
16. De Nunzio, C. & Tubaro, A. Prostate cancer: diabetes and prostate cancer-an open debate. Nat. Rev. Urol. 10, 12-14 (2012).
17. Djiogue, S. et al. Insulin resistance and cancer: the role of insulin and insulin-like growth factors. Endocr. Relat. Cancer 20, R1-R17 (2013).
18. Yuhara, H. et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am. J. Gastroenterol. 106, 1911-1921 (2011).
19. Wang, C. et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int. J. Cancer 130, 1639-1648 (2012).
20. Vongsuvanh, R., George, J., Qiao, L. & Poorten, D. V. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett. 330, 1-10 (2013).
21. McTiernan, A. Obesity and cancer: the risks, science, and potential management strategies. Oncology 19, 871-881 (2005).
22. Mannucci, E. Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol. 2012, 240634 (2012).
23. Bonelli, L. et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 27, 143-149 (2003).
24. Ding, X. Z., Fehsenfeld, D. M., Murphy, L. O., Permert, J. & Adrian, T. E. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 21, 310-320 (2000).
25. Maisonneuve, P. et al. Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann. Epidemiol. 20, 92-98 (2010).
26. Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M. & Abbruzzese, J. L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137, 482-428 (2009).
27. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. & Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305 (2005).
28. Chari, S. T. et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129, 504-511 (2005).
29. Gupta, S. et al. New-onset diabetes and pancreatic cancer. Clin. Gastroenterol. Hepatol. 4, 1366-1372 (2006).
30. Wang, F., Gupta, S. & Holly, E. A. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol. Biomarkers Prev. 15, 1458-1463 (2006).
31. Pannala, R. et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134, 981-987 (2008).
32. Krechler, T. et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 58, 58-64 (2011).
33. Cersosimo, E. et al. Insulin secretion and action in patients with pancreatic cancer. Cancer 67, 486-493 (1991).
34. Permert, J. et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur. J. Surg. 159, 101-107 (1993).
35. Saruc, M. & Pour, P. M. Diabetes and its relationship to pancreatic carcinoma. Pancreas 26, 381-387 (2003).
36. Kim, T. D. et al. Clinical characteristics of pancreatic cancer according to the presence of diabetes mellitus [Korean]. Korean J. Gastroenterol. 43, 35-40 (2004).
37. Wu, J. M. et al. Resolution of diabetes after pancreaticoduodenectomy in patients with and without pancreatic ductal cell adenocarcinoma. Ann. Surg. Oncol. 20, 242-249 (2013).
38. Trna, J., Dite, P., Adamcova, A., Crawford, B. J. & Hermanova, M. Diabetes mellitus in pancreatic cancer patients in the Czech Republic: sex differences. Exp. Diabetes Res. 2012, 414893 (2012).
39. Cuzick, J. & Babiker, A. G. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int. J. Cancer 43, 415-421 (1989).
40. Hiatt, R. A., Klatsky, A. L. & Armstrong, M. A. Pancreatic cancer, blood glucose and beverage consumption. Int. J. Cancer 41, 794-797 (1988).
41. Bell, E. T. Carcinoma of the pancreas. I. A clinical and pathologic study of 609 necropsied cases. II. The relation of carcinoma of the pancreas to diabetes mellitus. Am. J. Pathol. 33, 499-523 (1957).
42. Aggarwal, G., Rabe, K. G., Petersen, G. M. & Chari, S. T. New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology 12, 156-161 (2012).
43. Permert, J. et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur. J. Surg. 159, 101-107 (1993).
44. Chari, S. T., Klee, G. G., Miller, L. J., Raimondo, M. & DiMagno, E. P. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 121, 640-645 (2001).
45. Chari, S. T. et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134, 95-101 (2008).
46. Permert, J. et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br. J. Surg. 80, 1047-1050 (1993).
47. Aggarwal, G., Kamada, P. & Chari, S. T. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42, 198-201 (2013).
48. Tsoli, M. & Robertson, G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol. Metab. http://dx.doi.org/ 10.1016/j.tem.2012.10.006.
49. Fearon, K., Arends, J. & Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10, 90-99 (2013).
50. Fearon, K. C. et al. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J. Surg. 23, 584-588 (1999).
51. Gangi, S. et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am. J. Roentgenol. 182, 897-903 (2004).
52. Pelaez-Luna, M., Takahashi, N., Fletcher, J. G. & Chari, S. T. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am. J. Gastroenterol. 102, 2157-2163 (2007).
53. Permert, J. et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas 15, 60-68 (1997).
54. Basso, D. et al. β-cell function in pancreatic adenocarcinoma. Pancreas 9, 332-335 (1994).
55. Schwarts, S. S., Zeidler, A., Moossa, A. R., Kuku, S. F. & Rubenstein, A. H. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am. J. Dig. Dis. 23, 1107-1114 (1978).
56. Permert, J. et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N. Engl. J. Med. 330, 313-318 (1994).
57. Rosa, J. A., Van Linda, B. M. & Abourizk, N. N. New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review. J. Clin. Gastroenterol. 11, 211-215 (1989).
58. Silverstein, M. D., Richter, J. M., Podolsky, D. K. & Warshaw, A. L. Suspected pancreatic cancer presenting as pain or weight loss: analysis of diagnostic strategies. World J. Surg. 8, 839-845 (1984).
59. Girelli, C. M., Reguzzoni, G., Limido, E., Savastano, A. & Rocca, F. Pancreatic carcinoma: differences between patients with or without diabetes mellitus. Recenti Prog. Med. 86, 143-146 (1995).
60. Pannala, R. et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am. J. Gastroenterol. 104, 2318-2325 (2009).
61. Hart, P. A. et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 40, 768-772 (2011).
62. Murphy, R. A. et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin. Nutr. 29, 482-487 (2010).
63. Hermans, M. P., Levy, J. C., Morris, R. J. & Turner, R. C. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42, 678-687 (1999).
64. Hermans, M. P., Levy, J. C., Morris, R. J. & Turner, R. C. Comparison of tests of β-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 48, 1779-1786 (1999).
65. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840-846 (2006).
66. Chari, S. T., Zapiach, M., Yadav, D. & Rizza, R. A. β-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 5, 229-233 (2005).
67. Permert, J. et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N. Engl. J. Med. 330, 313-318 (1994).
68. Basso, D. et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin. Chim. Acta 372, 120-128 (2006).
69. Basso, D. et al. Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin. Chim. Acta 357, 184-189 (2005).
70. Aggarwal, G. et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology 143, 1510-1517 (2012).
71. Martinez, A. et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology 137, 2626-2632 (1996).
72. Sekine, N., Takano, K., Kimata-Hayashi, N., Kadowaki, T. & Fujita, T. Adrenomedullin inhibits insulin exocytosis via pertussis toxin-sensitive G protein-coupled mechanism. Am. J. Physiol. Endocrinol. Metab. 291, E9-E14 (2006).
73. Zudaire, E., Cuttitta, F. & Martinez, A. Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regu. Pept. 112, 121-130 (2003).
74. Hong, Y., Hay, D. L., Quirion, R. & Poyner, D. R. The pharmacology of adrenomedullin 2/intermedin. Br. J. Pharmacol. 166, 110-120 (2012).
75. Keleg, S. et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int. J. Cancer 121, 21-32 (2007).
76. Natsuizaka, M. et al. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp. Cell Res. 313, 3337-3348 (2007).
77. Konner, A. C. & Bruning, J. C. Selective insulin and leptin resistance in metabolic disorders. Cell. Metab. 16, 144-152 (2012).
78. Liu, J. et al. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J. Clin. Endocrinol. Metab. 85, 1232-1238 (2000).
79. Isaksson, B. et al. Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas 26, 173-177 (2003).
80. Basso, D. et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 24, 8-14 (2002).
81. Tabata, H. et al. Islet amyloid polypeptide (IAPP/amylin) causes insulin resistance in perfused rat hindlimb muscle. Diabetes Res. Clin. Pract. 15, 57-61 (1992).
82. Ding, X., Flatt, P. R., Permert, J. & Adrian, T. E. Pancreatic cancer cells selectively stimulate islet β cells to secrete amylin. Gastroenterology 114, 130-138 (1998).
83. Wang, F., Adrian, T. E., Westermark, G., Gasslander, T. & Permert, J. Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells. Pancreas 18, 403-409 (1999).
84. Wang, F. et al. Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int. J. Pancreatol. 21, 157-164 (1997).
85. Samuel, V. T. & Shulman, G. I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852-871 (2012).
86. Hardy, O. T., Czech, M. P. & Corvera, S. What causes the insulin resistance underlying obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19, 81-87 (2012).
87. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Ann. Rev. Physiol. 72, 219-246 (2010).
88. De Boer, M. P. et al. Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Microcirculation 19, 5-18 (2012).
89. Koerner, A., Kratzsch, J. & Kiess, W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract. Res. Clin. Endocrinol. Metab. 19, 525-546 (2005).
90. Matsuzawa, Y. Adiponectin: a key player in obesity related disorders. Curr. Pharm. Des. 16, 1896-1901 (2010).
91. Oda, N. et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 57, 268-273 (2008).
92. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Ann. Rev. Immunol. 29, 415-445 (2011).
93. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
94. Stienstra, R., Tack, C. J., Kanneganti, T. D., Joosten, L. A. & Netea, M. G. The inflammasome puts obesity in the danger zone. Cell. Metab. 15, 10-18 (2012).
95. Matsuzawa, Y. The metabolic syndrome and adipocytokines. FEBS Lett. 580, 2917-2921 (2006).
96. Grote, V. A. et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br. J. Cancer 106, 1866-1874 (2012).
97. Smits, M. M. & van Geenen, E. J. The clinical significance of pancreatic steatosis. Nat. Rev. Gastroenterol. Hepatol. 8, 169-177 (2011).
98. Gupta, D., Krueger, C. B. & Lastra, G. Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction. Curr. Diabetes Rev. 8, 76-83 (2012).
99. Tisdale, M. J. Zinc-α-2-glycoprotein in cachexia and obesity. Curr. Opin. Support Palliat. Care 3, 288-293 (2009).
100. Bing, C., Mracek, T., Gao, D. & Trayhurn, P. Zinc-α-2- glycoprotein: an adipokine modulator of body fat mass? Int. J. Obes. (Lond.) 34, 1559-1565 (2010).
101. Matsuzawa, Y. The role of fat topology in the risk of disease. Int. J. Obes. (Lond.) 32 (Suppl. 7), S83-S92 (2008).
102. Matsuzawa, Y., Funahashi, T. & Nakamura, T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J. Atheroscler. Thromb. 18, 629-639 (2011).
103. Matsuzawa, Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 86, 131-141 (2010).
104. McLaughlin, T., Lamendola, C., Liu, A. & Abbasi, F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J. Clin. Endocrinol. Metab. 96, E1756-E1760 (2011).
105. Klein, S. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350, 2549-2557 (2004).
106. Gabriely, I. et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51, 2951-8 (2002).
107. Thorne, A., Lonnqvist, F., Apelman, J., Hellers, G. & Arner, P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. (Lond.) 26, 193-199 (2002).
108. Ibrahim, M. M. Subcutaneous and visceral adipose tissue: structural and functional differences. Int. J. Obes. (Lond.) 11, 11-18 (2010).
109. Samaras, K., Botelho, N. K., Chisholm, D. J. & Lord, R. V. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity 18, 884-889 (2010).
110. Warburg, O. On respiratory impairment in cancer cells. Science 124, 269-270 (1956).
111. Regel, I. et al. Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbecks Arch. Surg. 397, 507-512 (2012).
112. Chaika, N. V. et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS ONE 7, e32996 (2012).
113. Dong, X. et al. Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev. Res. (Phila.) 4, 758-766 (2011).
114. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
115. Singh, P. K., Brand, R. E. & Mehla, K. MicroRNAs in pancreatic cancer metabolism. Nat. Rev. Gastroenterol. Hepatol. 9, 334-344 (2012).
116. Ferrer, J. Glucose as a mitogenic hormone. Cell Metab. 13, 357-358 (2011).
117. Jiao, L. et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 20, 1430-1438 (2011).
118. Jiao, L. et al. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 71, 3582-3589 (2011).
119. Han, L. et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS ONE 6, e27074 (2011).
120. Butler, A. E. et al. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 53, 21-26 (2010).
121. Li, J. et al. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS ONE 6, e17385 (2011).
122. Stolzenberg-Solomon, R. Z. et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294, 2872-2878 (2005).
123. Kang, R. et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc. Natl Acad. Sci. USA 109, 7031-7036 (2012).
124. Arumugam, T., Ramachandran, V., Gomez, S. B., Schmidt, A. M. & Logsdon, C. D. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin. Cancer Res. 18, 4356-4364 (2012).
125. Grote, V. A. et al. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. Cancer Epidemiol. Biomarkers Prev. 21, 619-628 (2012).
126. Jiao, L. et al. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 71, 3582-3589 (2011).
127. Muders, M. H. et al. Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Res. 66, 10264-10268 (2006).
128. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928 (2008).
129. Rozengurt, E., Sinnett-Smith, J. & Kisfalvi, K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16, 2505-2511 (2010).
130. Mehenni, H. et al. Cancer risks in LKB1 germline mutation carriers. Gut 55, 984-990 (2006).
131. Birnbaum, D. J. et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 50, 456-465 (2011).
132. Li, D. et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 33, 1384-1390 (2012).
133. Chaika, N. V. et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 α to regulate metabolism in pancreatic cancer. Proc. Natl Acad. Sci. USA 109, 13787-13792 (2012).
134. Akakura, N. et al. Constitutive expression of hypoxia-inducible factor-1 α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61, 6548-6554 (2001).
135. Chen, J. et al. Dominant-negative hypoxia-inducible factor-1 α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 162, 1283-12891 (2003).
136. Pannala, R., Basu, A., Petersen, G. M. & Chari, S. T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 10, 88-95 (2009).
137. Hardt, P. D., Brendel, M. D., Kloer, H. U. & Bretzel, R. G. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care 31 (Suppl. 2), S165-S169 (2008).
138. Chen, N., Unnikrishnan, I. R., Anjana, R. M., Mohan, V. & Pitchumoni, C. S. The complex exocrine-endocrine relationship and secondary diabetes in exocrine pancreatic disorders. J. Clin. Gastroenterol. 45, 850-861 (2011).
139. Diagnosis and classification of diabetes mellitus. Diabetes Care 33 (Suppl. 1), S62-S69 (2010).
140. Cui, Y. & Andersen, D. K. Pancreatogenic diabetes: special considerations for management. Pancreatology 11, 279-294 (2011).
141. Raue, G. & Keim, V. Secondary diabetes in chronic pancreatitis [German]. Z. Gastroenterol. (Suppl. 1), 4-9 (1999).
142. Tsuchiya, R. et al. Collective review of small carcinomas of the pancreas. Ann. Surg. 203, 77-81 (1986).
143. Permert, J., Herrington, M., Kazakoff, K., Pour, P. M. & Adrian, T. E. Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog. Carcinog. Mutagen. 21, 59-67 (2001).
144. Ahren, B. & Andren-Sandberg, A. Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res. Exp. Med. (Berl.) 193, 21-26 (1993).
145. Pour, P. M. & Bell, R. H. Alteration of pancreatic endocrine cell patterns and their secretion during pancreatic carcinogenesis in the hamster model. Cancer Res. 49, 6396-6400 (1989).
146. Basso, D. et al. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas 15, 132-138 (1997).
147. Valerio, A. et al. Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved. Biochem. Biophys. Res. Commun. 257, 622-628 (1999).
148. Basso, D. et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 53, 1159-1166 (2004).
149. Basso, D. et al. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res. 15, 2585-2588 (1995).
150. Wang, F., Larsson, J., Adrian, T. E., Gasslander, T. & Permert, J. In vitro influences between pancreatic adenocarcinoma cells and pancreatic islets. J. Surg. Res. 79, 13-19 (1998).